A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
about
Genome-editing Technologies for Gene and Cell TherapyChimeric Antigen Receptors Modified T-Cells for Cancer TherapyNovel immunotherapies in lymphoid malignanciesA new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19Progress and prospects for engineered T cell therapiesAdoptive T-cell therapy for LeukemiaChimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsT-cell receptor gene therapy--ready to go viral?T cell engineering as therapy for cancer and HIV: our synthetic futureLiver-targeted gene therapy: Approaches and challengesDNA transposon-based gene vehicles - scenes from an evolutionary driveZFN, TALEN, and CRISPR/Cas-based methods for genome engineeringmegaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering.Engineered T cells for cancer treatmentCRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor ImmunityGenome-Edited T Cell Therapies.Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.A versatile system for rapid multiplex genome-edited CAR T cell generationThe human application of gene therapy to re-program T-cell specificity using chimeric antigen receptorsHuman cell-based artificial antigen-presenting cells for cancer immunotherapy.TALEN and CRISPR/Cas Genome Editing Systems: Tools of Discovery.CRISPR/Cas9 for genome editing: progress, implications and challenges.A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Genetically engineered T cells for the treatment of cancer.Engineering T cell function using chimeric antigen receptors identified using a DNA library approachImproved cell-penetrating zinc-finger nuclease proteins for precision genome engineeringGene therapy for cancer: present status and future perspectiveGeneration of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of RasCytokine-induced killer (CIK) cells: from basic research to clinical translation.Genetically modified T-cell therapy for osteosarcomaSleeping Beauty transposon system for genetic etiological research and gene therapy of cancers.Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.Challenges and opportunities of allogeneic donor-derived CAR T cellsImmunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsEvaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
P2860
Q26769662-5FB02C07-A500-463A-BF52-9854EB5117EAQ26773309-ED92A39B-E3D4-4FCA-AFA3-1E86E85AE0C0Q26777394-3127D8BB-F495-47A5-A699-9E46C136A813Q26849476-E0B0EA15-CB86-4413-80E8-36D44C65E89EQ26852923-A0052572-8AD9-4702-9A03-FDF2008FB9ABQ27006934-82CF8B6A-66B2-45C6-966C-687224304182Q27312288-09C1F8EC-781C-4A5D-96D6-E9E6B8C09353Q28079823-789DE09B-1BCF-4801-9160-31F9DF8D3CEFQ28081611-EE4A20D0-304B-4F04-8430-871607EE7B5EQ28082253-BEC969AF-227E-4FA7-89F5-8816F51A540CQ28085748-44A7E087-4DB9-4647-BFD8-EBAA7C042BE6Q28660891-960FCB74-A670-43C6-A118-21FD547E8B3AQ29615505-DE882ED6-334C-43DE-8B24-19C72588E920Q30572833-49594B92-587B-4F94-8EFF-A2E2191328E4Q33578792-FBDC03A6-FE5D-436E-9DD1-20481E9E9612Q33671867-ABAEEE75-4A9E-4B50-84B4-D1D164A5C275Q33700795-ABFEC72A-03A4-4EBE-BAB7-FBBCE7AF3671Q33729598-BC00D5DF-C90B-4B2C-BB4F-7AFDA9FA5922Q34047618-A033BF93-0003-47FB-94AB-9BEC16139367Q34047977-156CDD77-BFC3-4A6D-B8C6-F93B19FB67B9Q34309388-D5D43FE8-C28D-49B8-AD85-507A753EA7CBQ34391263-F1398CF9-58AF-4C80-B2A6-378AF2C8484FQ34394269-26E0CB04-457E-4140-93C4-401CADEBD44DQ34411191-79F1F3C3-BA07-41A6-9861-9B2F67FA06ECQ34480145-E0D26129-4A40-46B8-98A5-25C3E9D7E0CFQ34517676-B0CDE842-BE20-4B2B-A70F-BA02C3C543EBQ34645898-524051FA-2EFF-4C20-9C8A-FADB9C9C4E9EQ34717977-5C5093BE-8876-4B17-86E5-4493C346EC60Q35161372-39EDFDCF-6FB5-46F2-8A39-004CED7A896EQ35673900-22A24F74-8F98-4967-8087-9183C1774FC7Q35878409-D972D92B-F425-41C0-8BF5-4364887E5092Q35980893-23244220-0A2B-41AC-9501-91814F0C856CQ36110284-E70376A2-71E5-4089-9966-3114B88C2695Q36121153-4FEAD2D9-FEA5-4ED1-8167-EA63289951FCQ36198232-1F2F1E1B-2FC0-47F9-8367-11748DA77A83Q36214663-8D2C5F2C-E3C0-464A-A388-A078BC4C5D75Q36248008-7A2EA4BD-6971-4F3E-A3AF-32319AF7F1B0Q36257036-ECA718FE-EC67-45F2-ADC4-9A277E4F40E0Q36470354-18540BA4-1999-4778-BC7E-13BAFA9BF633Q36675286-A04E61D9-6107-476D-9AF3-2AF2071C9DB6
P2860
A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A foundation for universal T-c ...... expression of endogenous TCR.
@ast
A foundation for universal T-c ...... expression of endogenous TCR.
@en
type
label
A foundation for universal T-c ...... expression of endogenous TCR.
@ast
A foundation for universal T-c ...... expression of endogenous TCR.
@en
prefLabel
A foundation for universal T-c ...... expression of endogenous TCR.
@ast
A foundation for universal T-c ...... expression of endogenous TCR.
@en
P2093
P2860
P1433
P1476
A foundation for universal T-c ...... expression of endogenous TCR.
@en
P2093
Andreas Reik
Brian Rabinovich
Chiara Bonini
Dean A Lee
Edward J Rebar
Helen Huls
Hiroki Torikai
Jeffrey C Miller
Laurence J N Cooper
Ling Zhang
P2860
P304
P356
10.1182/BLOOD-2012-01-405365
P407
P577
2012-04-24T00:00:00Z